{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:55:51Z","timestamp":1791442551057,"version":"4.3.3"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015471","name":"Mater Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104937","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:50:22Z","timestamp":1790095822000},"page":"104937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS\/MS and immunoassays for estradiol"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-6714","authenticated-orcid":false,"given":"Catherine M.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siun","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6169-1675","authenticated-orcid":false,"given":"Mohammed Z.","family":"Zamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Harrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-0355","authenticated-orcid":false,"given":"Shahid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Walshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-8652","authenticated-orcid":false,"given":"Michaela J.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-5737","authenticated-orcid":false,"given":"Caitriona","family":"Cahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mulready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9793","key":"10.1016\/j.breast.2026.104937_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"10001","key":"10.1016\/j.breast.2026.104937_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"3\u20135","key":"10.1016\/j.breast.2026.104937_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0960-0760(03)00365-0","article-title":"Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen","volume":"86","author":"Dowsett","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"10.1016\/j.breast.2026.104937_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104937_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104937_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104429","article-title":"Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+\/HER2- early breast cancer","volume":"81","author":"Janni","year":"2025","journal-title":"Breast"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104937_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.505","article-title":"15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS","volume":"43","author":"Francis","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10540","key":"10.1016\/j.breast.2026.104937_bib8","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(26)00313-2","article-title":"Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15\u2008000 women in 23 randomised trials","volume":"407","author":"Bradley","year":"2026","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2026.104937_bib9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104937_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104937_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P4-14-01","article-title":"Abstract P4-14-01: estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis","volume":"79","author":"Bellet","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2026.104937_bib12","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa047","article-title":"An ultrasensitive routine LC-MS\/MS method for estradiol and estrone in the clinically relevant sub-picomolar range","volume":"4","author":"Bertelsen","year":"2020","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.breast.2026.104937_bib13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1210\/jc.2012-3780","article-title":"Challenges to the measurement of estradiol: an endocrine society position statement","volume":"98","author":"Rosner","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.breast.2026.104937_bib14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/OP-24-00502","article-title":"Clinical management of ovarian function suppression in premenopausal women with Breast cancer: a survey of members of ASCO","volume":"21","author":"Kelly","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2026.104937_bib15","article-title":"Fulvestrant may falsely increase 17\u03b2-Estradiol levels in immunoassays: a case report of a 57-Year-Old postmenopausal patient with recurrent estrogen receptor-positive breast cancer","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104937_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41416-019-0378-9","article-title":"Oestradiol measurement during fulvestrant treatment for breast cancer","volume":"120","author":"Owen","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104937_bib17","series-title":"Mannheim, Germany: Roche diagnostics","article-title":"Method Sheet and performance characteristics. Elecsys\u00ae Estradiol III Systems : cobas e 402, cobas e 801","author":"GmbH","year":"2023"},{"issue":"3","key":"10.1016\/j.breast.2026.104937_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-024-07439-y","article-title":"Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression","volume":"207","author":"Kessler","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104937_bib19","article-title":"Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy","volume":"9","author":"Kessler","year":"2023","journal-title":"Curr Probl Cancer: Case Reports"},{"key":"10.1016\/j.breast.2026.104937_bib20","series-title":"MAUDE adverse event report: abbott Ireland diagnostics division alinity I estradiol reagent kit; radioimmunoassay, estradiol","year":"2024"},{"key":"10.1016\/j.breast.2026.104937_bib21","unstructured":"Forster R MF, Dolan M, Stephenson A, Hawley J, and Marrington R. : Interference in Estradiol assays from Hormone Therapies used in Breast Cancer Treatment. In."},{"issue":"16","key":"10.1016\/j.breast.2026.104937_bib22","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2026.104937_bib23","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-Month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13058-025-01979-x","article-title":"Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy","volume":"27","author":"Patel","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2026.104937_bib25","doi-asserted-by":"crossref","first-page":"e936","DOI":"10.1002\/onco.13722","article-title":"Measuring ovarian escape in premenopausal estrogen receptor-positive breast cancer patients on ovarian suppression therapy","volume":"26","author":"Burns","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-024-00680-0","article-title":"Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy","volume":"10","author":"Tesch","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104937_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clbc.2023.03.009","article-title":"Ovarian function suppression in premenopausal women with concurrent endocrine therapy use","volume":"23","author":"Fleege","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104937_bib28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/jnci\/djae115","article-title":"Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer","volume":"116","author":"Lin","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2026.104937_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-024-07323-9","article-title":"Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study","volume":"206","author":"Chen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12282-016-0691-6","volume":"24","author":"Kurebayashi","year":"2017","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12032-012-0354-1","article-title":"Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients","volume":"30","author":"Aydiner","year":"2012","journal-title":"Med Oncol"},{"issue":"18","key":"10.1016\/j.breast.2026.104937_bib32","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate Every-3-Months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104937_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inf"},{"key":"10.1016\/j.breast.2026.104937_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inf"},{"issue":"Pt 3","key":"10.1016\/j.breast.2026.104937_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/0004563213501478","article-title":"A rapid direct assay for the routine measurement of oestradiol and oestrone by liquid chromatography tandem mass spectrometry","volume":"51","author":"Owen","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.breast.2026.104937_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103818","article-title":"Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer","volume":"78","author":"Dai","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104937_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-024-07323-9","article-title":"Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study","author":"Chen","year":"2024","journal-title":"Breast Cancer Res Treat, 206,"},{"issue":"5","key":"10.1016\/j.breast.2026.104937_bib38","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1016\/j.clbc.2018.04.005","article-title":"Efficacy of different leuprolide administration schedules in premenopausal breast cancer: a retrospective review","volume":"18","author":"Kendzierski","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104937_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106079","article-title":"Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study","volume":"11","author":"Valenza","year":"2026","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.breast.2026.104937_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6574","article-title":"Ovarian function suppression in premenopausal patients with concurrent endocrine therapy use","volume":"39","author":"Grogan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-024-00614-w","article-title":"Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer","volume":"10","author":"McCann","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104937_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1677\/joe.0.0700421","article-title":"Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women","volume":"70","author":"Groom","year":"1976","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.breast.2026.104937_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9378(96)70386-1","article-title":"Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer","volume":"174","author":"Shushan","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.breast.2026.104937_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:47:49Z","timestamp":1791442069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"alternative-id":["S096097762600247X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104937","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS\/MS and immunoassays for estradiol","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104937"}}